Zyesami FDA Approval Status
FDA Approved: No
Brand name: Zyesami
Generic name: aviptadil
Company: NRx Pharmaceuticals
Treatment for: COVID-19
Zyesami (aviptadil) is an inhaled formulation of synthetic human Vasoactive Intestinal Polypeptide (VIP) in development for the treatment of patients with critical COVID-19 respiratory failure.
Development timeline for Zyesami
| Date | Article |
|---|
| Nov 4, 2021 | US Food and Drug Administration Declines Emergency Use Authorization for Zyesami (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure |
| Oct 14, 2021 | Journal of Infectious Diseases and Treatment Publishes Positive Trial Data of Aviptadil in High Comorbidity Patients Suffering from Critical COVID-19 with Respiratory Failure |
| Aug 18, 2021 | NRx Pharmaceuticals Announces Positive Safety Report for Zyesami (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19 |
| Apr 6, 2021 | NeuroRx Announces Zyesami (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir |
| Sep 23, 2020 | NeuroRx Submits Request for Emergency Use Authorization for RLF-100™ (aviptadil) in the Treatment of Patients with Critical COVID-19 and Respiratory Failure Who Have Exhausted Approved Therapy |
| Aug 6, 2020 | FDA Grants Inhaled Use IND for RLF-100 (aviptadil) to Treat Patients with Moderate and Severe COVID-19 Aiming to Prevent Progression to Respiratory Failure |
| Aug 3, 2020 | RLF-100 (aviptadil) Clinical Trial Showed Rapid Recovery from Respiratory Failure and Inhibition of Coronavirus Replication in Human Lung Cells |
| Jun 24, 2020 | NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19 |
| May 6, 2020 | Relief Therapeutics Holding Drug Aviptadil Enters FDA Trial at NYU Langone Health, New York, to Treat COVID-19-induced Acute Respiratory Distress |
| May 4, 2020 | Relief Therapeutics Holding Drug Aviptadil Enters FDA Trial at University of California Irvine, to Treat COVID-19-Induced Acute Respiratory Distress |
| Apr 9, 2020 | Relief Therapeutics Drug Aviptadil Enters FDA Trial at Thomas Jefferson University Hospital in Philadelphia, to treat COVID-19-Induced Acute Respiratory Distress |
| Apr 7, 2020 | Relief Therapeutics' Drug Aviptadil Enters FDA Trial at University of Miami to Treat COVID-19-Induced Respiratory Distress |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer
